Spark and Roche Update on Hemophilia Gene Therapy Program

April 22, 2020

The following is an update on the Spark and Roche gene therapy program. “Together, Spark and Roche remain fully committed in our objective to meet the needs of the hemophilia community by developing gene therapies for hemophilia A that, with the lowest effective dose and optimal regimen to manage the immune system response, demonstrate safety, […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.